Andere Kunden interessierten sich auch für
![Entry Inhibitors in HIV Therapy]( "Entry Inhibitors in HIV Therapy")
Entry Inhibitors in HIV Therapy110,99 €![Treatment and Prevention of Malaria]( "Treatment and Prevention of Malaria")
Treatment and Prevention of Malaria160,49 €![Drug Target Selection and Validation]( "Drug Target Selection and Validation")
Drug Target Selection and Validation103,99 €![Complement Therapeutics]( "Complement Therapeutics")
Complement Therapeutics110,99 €![Drug Target Selection and Validation]( "Drug Target Selection and Validation")
Drug Target Selection and Validation149,79 €![Twenty Years of G-CSF]( "Twenty Years of G-CSF")
Twenty Years of G-CSF147,99 €![Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics]( "Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics")
Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics131,99 €
Influenza continues to be an ongoing problem despite the existence of vaccines and drugs. Disease outbreaks can occur relatively quickly as witnessed with the recent emergence of the influenza virus A/H1N1 pandemic. The development of new anti-influenza drugs is thus a major challenge.
This volume describes all aspects of the virus structure and function relevant to infection. The focus is on drug discovery of inhibitors to the enzyme sialidase, which plays a key role in the infectious lifecycle of the virus. Following an overview of the influenza virus, the haemagglutinin, the interactions with the cell receptors and the enzymology of virus sialidase, recent results in drug design are presented. These include a full coverage of the design, synthesis and evaluation of carbohydrate as well as non-carbohydrate influenza virus sialidase inhibitors. Further reviews of the clinical experience with influenza virus sialidase inhibitors and of the development of resistance tothese inhibitor drugs complement the topic.
This volume describes all aspects of the virus structure and function relevant to infection. The focus is on drug discovery of inhibitors to the enzyme sialidase, which plays a key role in the infectious lifecycle of the virus. Following an overview of the influenza virus, the haemagglutinin, the interactions with the cell receptors and the enzymology of virus sialidase, recent results in drug design are presented. These include a full coverage of the design, synthesis and evaluation of carbohydrate as well as non-carbohydrate influenza virus sialidase inhibitors. Further reviews of the clinical experience with influenza virus sialidase inhibitors and of the development of resistance tothese inhibitor drugs complement the topic.